Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Mar 3;8(3):e251689.
doi: 10.1001/jamanetworkopen.2025.1689.

Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial

Jelle M Beernink  1   2 , Niels Jongs  1 , Cees J A Doelman  3 , Gozewijn D Laverman  2   4 , Hiddo J L Heerspink  1
Affiliations
Randomized Controlled Trial

Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial

Jelle M Beernink et al. JAMA Netw Open. .

Abstract

Importance: Dapagliflozin reduces the urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) decline at a population level, but individuals show a large variation in responses. The n-of-1 trial design allows for direct assessment of treatment effects within an individual, and digital technologies and remote study assessments can reduce clinic visits, ease participant burden, and improve trial efficiency.

Objective: To assess individual UACR responses to dapagliflozin treatment in a decentralized clinical trial and the feasibility of remote data collection.

Design, setting, and participants: This decentralized, randomized, double-blind, placebo-controlled crossover trial using an n-of-1 approach was conducted using data from the Dutch primary and secondary health care systems between May 2021 and September 2022. Participants included adults with type 2 diabetes, a UACR greater than 20 mg/g, and an eGFR greater than 30 mL/min/1.73 m2. Statistical analyses were performed between June and August 2023.

Interventions: Participants were assigned to two 1-week treatment periods with dapagliflozin, 10 mg/d, and two 1-week treatment periods with placebo in random order, with 1-week washout periods in between.

Main outcomes and measures: The primary outcome was the difference in the change in UACR from start to end of treatment between dapagliflozin and placebo in the per-protocol population. A post hoc exploratory analysis assessed the feasibility of remote data collection, including the proportion of urine and capillary blood samples successfully delivered to the central laboratory.

Results: In total, 20 participants (mean [SD] age, 64.9 [8.7] years; 17 [85.0%] male) with a mean (SD) eGFR of 70.2 (20.3) mL/min/1.73 m2 and a median UACR of 94.7 (IQR, 29.8-242.6) mg/g were included in the study. They experienced a relative change in UACR with dapagliflozin compared with placebo of -15.1% (95% CI, -28.2% to -3.3%; P = .01). UACR changes showed considerable variation during both dapagliflozin and placebo treatment (first treatment period: median, -12.8% [range, -56.3% to 36.2%] and 2.9% [range, -86.7% to 35.1%], respectively). UACR changes correlated significantly between the first and second dapagliflozin exposure (r = 0.50; P = .03), with no correlation observed between the placebo exposure periods (r = 0.09; P = .69). With regard to remote data collection, 811 of 816 urine samples (99.4%) and 433 of 440 capillary blood samples (98.4%) were successfully delivered to the central laboratory.

Conclusions and relevance: In this crossover trial, individual UACR responses to dapagliflozin reflected a pharmacological response. Remote data collection proved to be reliable, supporting its use in future studies and clinical practice for monitoring individual dapagliflozin responses.

Trial registration: EudraCT identifier: 2020-004929-23.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Beernink reported receiving a Kolff+ Program grant from the Dutch Kidney Foundation during the conduct of the study and receiving grants and travel support from AstraZeneca outside the submitted work. Dr Jongs and Prof Laverman reported receiving grants from AstraZeneca outside the submitted work. Prof Laverman also reported receiving personal fees from AstraZeneca, Janssen, and Sanofi and serving as a consultant for AbbVie, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Merck Sharp & Dohme, and Sanofi. Prof Heerspink reported receiving honoraria paid to his institution (University Medical Center Groningen) for participation in steering committees or advisory boards of Alexion, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, Idorsia, Janssen, Novartis, Novo Nordisk, Roche, and Travere Therapeutics and receiving research grants from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Flow Diagram of Study Participants
Order 1 was placebo, dapagliflozin, placebo, and dapagliflozin; order 2, placebo, dapagliflozin, dapagliflozin, and placebo; order 3, dapagliflozin, placebo, dapagliflozin, and placebo; and order 4, dapagliflozin, placebo, placebo, and dapagliflozin.
Figure 2.
Figure 2.. Changes in Urine Albumin-to-Creatinine Ratio (UACR) During Treatment With Dapagliflozin and Placebo
Error bars indicate 95% CIs.
Figure 3.
Figure 3.. Mean Change in Urine Albumin-to-Creatinine Ratio (UACR) and Individual Participant UACR Changes During Dapagliflozin and Placebo Treatment Periods
Box plots demonstrate median (horizontal line in middle of box), mean (diamond), IQR (box top and bottom), and maximum and minimum UACR changes (whiskers).
Figure 4.
Figure 4.. Correlation in Percentage Urine Albumin-to-Creatinine Ratio (UACR) Changes During First and Second Exposure to Dapagliflozin and Placebo
See this image and copyright information in PMC

Comment in

  • doi: 10.1001/jamanetworkopen.2025.1702

References

    1. American Diabetes Association . (9) Microvascular complications and foot care. Diabetes Care. 2015;38(1)(suppl):S58-S66. doi:10.2337/dc15-S012 - DOI - PubMed
    1. Heerspink HJL, Sjöström CD, Inzucchi SE, et al. . Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. Diabetes Obes Metab. 2019;21(3):720-725. doi:10.1111/dom.13579 - DOI - PMC - PubMed
    1. Wanner C, Inzucchi SE, Lachin JM, et al. ; EMPA-REG OUTCOME Investigators . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334. doi:10.1056/NEJMoa1515920 - DOI - PubMed
    1. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-2233. doi:10.1016/S0140-6736(10)60407-2 - DOI - PubMed
    1. Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211-220. doi:10.1016/S2213-8587(15)00417-9 - DOI - PubMed

Publication types